Side-by-side · Research reference
LivagenvsMGF
Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.
AAnimal-StrongHUMAN-REVIEWED20/32 cited
BAnimal-StrongHUMAN-REVIEWED14/55 cited
Livagen
Khavinson Bioregulator · Hepatoprotective Tetrapeptide
Oral or SQ · Tissue-specific to liver
MGF
IGF-1Ec Splice Variant · Muscle-Specific
SQ · Research context only
01Mechanism of Action
Parameter
Livagen
MGF
Primary target
Hepatocyte protein synthesis machineryBrodskiĭ 2001
Satellite cells (Pax7+) in skeletal muscleMoore 2018
Pathway
Tissue-specific bioregulator → Hepatocyte stimulation → Protein synthesis normalizationBrodskiĭ 2001Khavinson 2001
Mechanical stress → IGF-1Ec mRNA upregulation → Local E-domain peptide release → Satellite cell activation
Downstream effect
Age-dependent enzyme normalization, hepatoprotection in fibrosis/hepatitis models, elevated protein synthesis in senescent hepatocytes
Satellite cell proliferation, myoblast differentiation, muscle fiber repair
Feedback intact?
—
—
Origin
Directed chemical synthesis from amino acid analysis of liver polypeptide preparations (Ventvil)
Alternative splicing of IGF-1 gene (exons 4-6) produces IGF-1Ec precursor; E-domain cleaved post-translationallyArmakolas 2016Vassilakos 2017
Antibody development
—
—
02Dosage Protocols
Parameter
Livagen
MGF
Animal dose (oral)
Not specified in abstracts; 2-week administration protocolTimofeeva 2005
Per os administration in rats.
—
Duration (experimental)
2 weeks (enzyme study); up to 24 months (cell culture)Timofeeva 2005Brodskiĭ 2001
—
Route
Oral or subcutaneous
Resists peptidase hydrolysis, enabling oral bioavailability.Timofeeva 2005
—
Evidence basis
Animal models (rats, 1–24 months age); in vitro hepatocyte cultureTimofeeva 2005Brodskiĭ 2001Khavinson 2002
Animal models + in vitro only
Human data
None in provided literature
—
Synthetic peptide
—
24-amino-acid E-domain sequence
Corresponds to human IGF-1Ec exons 4-6 region.
Rodent cardiac model
—
200 μg/kg via peptide-eluting microstructures
Post-MI injection; improved ejection fraction by 8 weeks.
Acute delivery (mouse MI)
—
Single bolus within 12 hrs post-infarctionShioura 2014
Delayed decompensation; no human protocol established.
Human evidence
—
None — no published clinical trials
All dosing extrapolated from animal models.
Detection in doping
—
Full-length MGF detected via LC-MS in illicit productsThevis 2014
WADA-prohibited since 2005; no therapeutic indication.
04Side Effects & Safety
Parameter
Livagen
MGF
Reported adverse effects
None documented in animal studies
—
Human safety data
No human trials in provided literature
None — no clinical trials published
Theoretical IGF-1 axis risk
—
Chronic IGF-1Ec overexpression linked to cancer progression (prostate, colorectal, breast)
Tumor promotion
—
IGF-1Ec overexpressed in osteosarcoma, colorectal polyps with dysplasia, endometrial cancer
Antibody development
—
Unknown — no longitudinal human exposure data
Local injection reaction
—
Presumed similar to other peptides (erythema, induration) — no direct evidence
Dysregulated expression with age
—
Older adults (70+ yrs) show blunted IGF-1Ec response post-exercise vs youngMoore 2018
Absolute Contraindications
Livagen
—MGF
- ·Active malignancy or history of IGF-1-sensitive cancers (prostate, colorectal, breast, osteosarcoma)
- ·No established therapeutic use — investigational only
Relative Contraindications
Livagen
—MGF
- ·Family history of IGF-1-axis malignancies
- ·Use outside research setting
05Administration Protocol
Parameter
Livagen
MGF
1. Route selection
Oral administration supported by peptidase resistance. Subcutaneous route used in organotypic culture experiments.Timofeeva 2005Khavinson 2001
MGF (E-domain peptide) has no approved clinical protocol. All published data derive from animal models or in vitro experiments.
2. Timing
No specific timing documented. Two-week protocols used in animal models with daily administration.Timofeeva 2005
Commercially available MGF corresponds to the 24-amino-acid human E-domain (hEc). Rodent E-domain (Eb) is structurally distinct and not interchangeable.
3. Age-dependent response
Elderly individuals may exhibit different enzyme normalization patterns than younger cohorts, based on rat age-stratified findings.Timofeeva 2005
Rodent studies used peptide-eluting polymeric microstructures (cardiac) or direct intramuscular injection. Routes and doses non-translatable to humans.Peña 2015Shioura 2014
4. WADA prohibition
—
MGF peptides prohibited in sport since 2005. Detection via LC-MS established for full-length MGF products.Thevis 2014
5. Research context only
—
Any human use falls outside approved medical practice and regulatory frameworks. No safety or efficacy data exist.
06Stack Synergy
Livagen
— no documented stacks
MGF
+ BPC-157
Multi-pathwayMGF activates satellite cells for muscle fiber repair; BPC-157 promotes angiogenesis, collagen synthesis, and tendon healing via distinct pathways (VEGF, FAK, integrin signaling). Theoretical synergy in post-injury contexts combines myogenic (MGF) and stromal (BPC-157) repair mechanisms. Both lack human validation.
- MGF
- No established dose
- BPC-157
- 250–500 mcg SQ near injury site
- Context
- Animal models only
- Primary benefit
- Theoretical multi-tissue repair (muscle + tendon/ligament)
+ TB-500
ModerateTB-500 (thymosin beta-4 fragment) enhances actin polymerization, cell migration, and angiogenesis—complementary to MGF satellite cell activation. Both upregulated post-injury; combined use presumed additive for muscle regeneration in preclinical models.
- MGF
- No established dose
- TB-500
- 2–5 mg SQ weekly
- Context
- Animal models only
- Primary benefit
- Satellite cell activation + enhanced migration/angiogenesis